Author:
Earl H M, ,Hiller L,Dunn J A,Bathers S,Harvey P,Stanley A,Grieve R J,Agrawal R K,Fernando I N,Brunt A M,McAdam K,O'Reilly S,Rea D W,Spooner D,Poole C J
Publisher
Springer Science and Business Media LLC
Reference14 articles.
1. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez Nj, Filiberti A, Flechtner H, Fleishman Sb, Dehaes Jcjm, Kaasa S, Klee M, Osoba D, Razavi D, Rofe Pb, Schraub S, Sneeuw K, Sullivan M, Takeda F (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85: 365–376
2. Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C (1995b) Cyclophosphamide, methotrexate and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 332: 901–906
3. Bonadonna G, Zambetti M, Valagussa P (1995a) Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. J Am Med Assoc 273: 542–547
4. Early Breast Cancer Trialists' Collaborative Group (1990) Introduction and Methods Sections, Treatment of Early Breast Cancer, Vol. 1. Worldwide Evidence 1985–1990. Oxford University Press: England
5. Hryniuk W, Bush H (1984) The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 2: 1281–1288
Cited by
22 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献